Biotech Startups

A biotechnology company that develops creative biotech solutions to improve human health and well-being.

1 investor

Lingtaike Biotech develops nucleic acid drugs based on lncRNA, using its proprietary lncRNA-mediated targeting chimera technology (lncTAC) combined with the UNAST platform to target traditionally undruggable disease targets. The company focuses on drug discovery for unmet clinical needs in the lncRNA field.

1 investor

1 investor

LogicFlo builds task-specialized AI agents organized into coordinated "desks" (research, writing, review) that handle medical affairs and scientific content work such as MSL decks, manuscripts, literature reviews, and MLR-ready content for life sciences and biopharma teams. The platform integrates with enterprise systems like Veeva and SharePoint and is built for regulated environments with SOC 2, ISO 27001, and HIPAA compliance.

1 investor

Lomond Therapeutics is a small molecule oncology drug discovery company developing differentiated therapies that target biological pathways with resistant mutations and escape mechanisms in hematologic malignancies. It focuses on pan-variant therapies aimed at overcoming resistance in current cancer treatments.

1 investor

Longenesis operates a platform for health and biomedical data management used to run research studies, including managing study participants across the Baltics and Mediterranean regions. It partners with genomics providers to offer services such as whole genome sequencing to study participants.

1 investor

The Longevity Science Foundation funds scientific research to address the biological drivers of women's health disparities, particularly ovarian aging and menopause. The foundation is raising capital to simultaneously advance measurement technologies, biological understanding, and early-stage interventions targeting reproductive aging.

1 investor

The Longevity Fund is a venture capital firm founded in 2011 to back founder-led biotech companies developing drugs for longevity and age-related diseases. It has since relaunched as a new fund under the name age1.

1 investor

The Longevity Biotechnology Association is a global non-profit organization that convenes longevity biotech companies, pharmaceuticals, researchers, and investors to establish industry standards and advance the translation of geroscience into therapeutic interventions that prevent age-related diseases and extend health span.

1 investor

Longwood Fund is a biotech-focused investment firm that both creates and invests in early-stage biotechnology companies developing therapies for unmet medical needs. The team combines decades of experience in biotech investing, operating, and building, working with companies from seed through clinical proof of concept.

1 investor

Loop Diagnostics develops an in vitro cellular immunoassay that detects immunosuppression from bloodstream infections, including sepsis, within the first hour of infection to enable earlier treatment. The company serves healthcare providers with a diagnostic tool for early sepsis detection.

1 investor

Loopworm uses silkworm farming infrastructure to produce sustainable proteins for animal nutrition and biopharmaceutical applications. The company operates industrial-scale production of functional ingredients for aquaculture, pets, and livestock, while developing recombinant proteins for healthcare, diagnostics, and specialty enzymes.

1 investor

LORAI Health develops next-generation transdermal drug delivery technologies for medicines such as hormones, pain therapies, and neurological treatments, with a focus on reliable delivery, patient comfort, and manufacturing resilience. Founded in Australia, it originated in menopausal hormone therapy and works with research, manufacturing, healthcare, and investment partners internationally.

1 investor

Thryv Therapeutics is a clinical-stage biotechnology company developing selective inhibitors of serum glucocorticoid inducible kinase 1 (SGK1) for inherited cardiac arrhythmias such as Long QT Syndrome and acquired cardiometabolic diseases. Its lead compound, THRV-1268, is in a Phase 2/3 clinical study for Long QT Syndrome Type 2.

1 investor

LTL Pharma acquires and develops long-established pharmaceutical drugs (long-life medications) from originator manufacturers, maintaining consistent supply and quality standards for healthcare providers and patients. The company specializes in managing mature pharmaceutical products with extensive clinical track records.

1 investor

LTZ Therapeutics is a clinical-stage biotechnology company developing myeloid cell-engaging immunotherapies to boost anti-tumor immunity against cancer. Its approach directs myeloid cells to kill tumor cells and reprogram the tumor microenvironment, with a lead candidate (LTZ-232) targeting advanced metastatic colorectal cancer and other solid tumors.

1 investor

Daopei is a group of specialty hospitals in China focused on blood diseases, offering hematopoietic stem cell transplantation, chemotherapy, immunotherapy (including CAR-T), and pathology/laboratory diagnostics for patients with leukemia, lymphoma, myeloma, and other hematological conditions. It operates multiple facilities in Beijing, Shanghai, and Hebei.

1 investor

Lucence develops blood-based diagnostic tests for early cancer detection, hereditary and health risk assessment, treatment selection, and treatment response monitoring. Its liquid biopsy and tissue tests serve oncology patients and clinicians across multiple solid tumors and hematological cancers, available internationally and in the USA.

1 investor

Lucid Diagnostics develops tests for the early detection of esophageal precancer using targeted next-generation sequencing, aimed at helping clinicians detect and treat the condition before it progresses to cancer. The company operates a CLIA-certified, CAP-accredited clinical lab licensed by the New York State Department of Health.

1 investor

Lucid Genomics provides a software platform for genomic analysis tailored to clinicians, specializing in long-read sequencing interpretation for rare disease, hereditary cancer, and pharmacogenomics diagnostics. The platform integrates variant calling, prioritization, interpretation, and reporting with HPO-based phenotype matching and advanced visualization tools for structural variants.

1 investor

Lucina Biotherapeutics develops therapeutics to treat aging-related disorders, particularly dry age-related macular degeneration (AMD), by restoring very long-chain polyunsaturated fatty acids (VLC-PUFAs) in tissues through its PUFActive platform. The company employs two approaches: synthetic VLC-PUFA formulations for intravitreal injection and engineered microorganism biofactories for oral delivery.

1 investor

LUMABS BV develops RAPPID, a rapid, one-step immunoassay technology that enables sensitive antibody detection from minimal blood samples for diagnostics and therapeutic monitoring. The company serves immunoassay diagnostic companies, clinical laboratories, biotech organizations, and research groups seeking faster, more sensitive alternatives to traditional ELISA-based assays.

1 investor

Lumen develops orally delivered antibody drugs using engineered spirulina, a patented biologic platform that reduces manufacturing costs and timelines compared to conventional biologics. The company serves biopharma customers seeking alternatives to traditional drug manufacturing.

1 investor

Lumena Pharmaceuticals develops pharmaceutical, nutraceutical, and testing service products using biotechnology, with a focus on ethical practices in research, manufacturing, and distribution across health care markets. The company prioritizes environmental sustainability, reduced chemical use, and responsible innovation in bioavailable product development.

1 investor